Trending...
- HOPE fills the Seaside Heights boardwalk for the tenth straight year
- Long Island businessman turned recording artist, John Beyer, to release his first love song aptly titled, …"Love You More"
- North Carolina Entrepreneur Awarded 2023 Small Business Advocate of the Year By NSBA
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company's common stock for the fourth quarter of 2022. Payment will be made on Oct. 7, 2022, to shareholders of record at the close of business on Sept. 15, 2022.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
More on Jersey Desk
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
More on Jersey Desk
Contacts
Media:
Johanna Herrmann, (617) 216-6029
Melissa Moody, (215) 407-3536
Investor:
Peter Dannenbaum, (908) 740-1037
Steven Graziano, (908) 740-6582
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.
More on Jersey Desk
- Wave2 Launches New Dynamic Data Integration Features to Elevate Bank and Credit Union Convenience
- Texas Advocacy Project Aids 10k+ Abuse Victims Annually; Offers Subject Matter Experts for Domestic Violence Awareness Month
- Introducing Stack & Sprout: The Revolutionary Vertical Plant Growing System for Urban Gardeners
- Higi Selects ThoroughCare to Assist in Managing Chronically Ill Patients
- Introducing the State-of-the-Art National Security Operations Center: Enhancing Safety and Vigilance Nationwide
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2021 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).
More on Jersey Desk
- August 2023 Financial Market Review
- Lane Music Partners with Nashville International Chopin Piano Competition
- "Art Palooza" – Party & Auction Fundraiser for The Center for Contemporary Art
- New Study Finds Wide Disparities in Bicycle Safety Across U.S. Cities
- Wellsboro, Pennsylvania Named Ninth Best Fall Town in the U.S. for Foliage
Contacts
Media:
Johanna Herrmann, (617) 216-6029
Melissa Moody, (215) 407-3536
Investor:
Peter Dannenbaum, (908) 740-1037
Steven Graziano, (908) 740-6582
Filed Under: Business
0 Comments
Latest on Jersey Desk
- Long Island businessman turned recording artist, John Beyer, to release his first love song aptly titled, …"Love You More"
- The 2023 CGI Integrated Care Conference Explores Opportunities in Healthcare Improvement Discovered as a Result of the COVID-19 Pandemic
- Exploring the World of Web3? Lympid Puts Users Front and Center
- "Regenerating Life": documentary film challenges current assumptions about climate change
- Flint's Got Talent Returns To Showcase Creativity In Community
- Autonomous eVTOLs $25 Billion Market by 2030
- Global Life Settlement Exchange: Selling a Life Insurance Policy Might be a Better Option Than Letting it Lapse or Surrendering it
- Jiritsu Raises $10.2 Million in Funding to Revolutionize Verifiable Compute
- Heartland Soccer Set to Host Sold Out Midwest All Boys Tournament this Weekend
- Material Capital Partners Completes Exit of The Preserve at Sweetwater, Expands BFR Pipeline in the Southeast
- HOPE fills the Seaside Heights boardwalk for the tenth straight year
- GetFreeFunds.com Connects COVID-Hit Businesses To Free Government Funds
- Tobu Railway Launches Its Latest Model "Spacia X" Express Train with 40% Reduced CO2 Emissions Compared with the Previous Spacia Fleet
- Axiros Launches a New Release of their USP Agent - AXACT 2023.4
- Cognizant selected by Intrum to support its digital transformation English English
- North Carolina Entrepreneur Awarded 2023 Small Business Advocate of the Year By NSBA
- Instant Gourmet Coffee With The Authentic Taste & Refreshing Smell Of Cafe De Olla, Infused With The Wonderful Health Benefits Of Superfoods
- Berlin Packaging Fires Female Executive Following Complaints of Discrimination
- Things First-Time Home Sellers Wish They'd Been Told
- Falcomm selected for 2023 TechCrunch Startup Battlefield 200